MA29817B1 - Derives de prolinamide utilises comme modulateurs du canal sodium - Google Patents
Derives de prolinamide utilises comme modulateurs du canal sodiumInfo
- Publication number
- MA29817B1 MA29817B1 MA30797A MA30797A MA29817B1 MA 29817 B1 MA29817 B1 MA 29817B1 MA 30797 A MA30797 A MA 30797A MA 30797 A MA30797 A MA 30797A MA 29817 B1 MA29817 B1 MA 29817B1
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- sodium channel
- prolinamide derivatives
- prolinamide
- derivatives
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title abstract 2
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical class NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 title 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520581A GB0520581D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
| GB0523045A GB0523045D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
| GB0603900A GB0603900D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
| GB0618336A GB0618336D0 (en) | 2006-09-18 | 2006-09-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29817B1 true MA29817B1 (fr) | 2008-09-01 |
Family
ID=37546777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30797A MA29817B1 (fr) | 2005-10-10 | 2008-03-31 | Derives de prolinamide utilises comme modulateurs du canal sodium |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7655693B2 (https=) |
| EP (1) | EP1934177B8 (https=) |
| JP (1) | JP5139305B2 (https=) |
| KR (1) | KR101282464B1 (https=) |
| AR (1) | AR056575A1 (https=) |
| AT (1) | ATE556049T1 (https=) |
| AU (1) | AU2006301470B2 (https=) |
| BR (1) | BRPI0616944B8 (https=) |
| CA (1) | CA2625642C (https=) |
| CR (1) | CR9898A (https=) |
| EA (1) | EA015736B1 (https=) |
| ES (1) | ES2387405T3 (https=) |
| IL (1) | IL192627A0 (https=) |
| MA (1) | MA29817B1 (https=) |
| NO (1) | NO20082145L (https=) |
| NZ (1) | NZ567051A (https=) |
| PE (1) | PE20070592A1 (https=) |
| PL (1) | PL1934177T3 (https=) |
| TW (1) | TW200730494A (https=) |
| WO (1) | WO2007042239A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143306B2 (en) * | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| ATE472529T1 (de) * | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| WO2011015537A1 (en) * | 2009-08-05 | 2011-02-10 | Glaxo Group Limited | Co-therapy for the treatment of epilepsy and related disorders |
| JP5855000B2 (ja) * | 2009-09-14 | 2016-02-09 | クオンベルゲンセ プハルマセウトイカルス リミテッド | α−カルボキサミド誘導体の製造方法 |
| EP2681200A4 (en) | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| EP3110794A1 (en) | 2014-02-27 | 2017-01-04 | Merck Patent GmbH | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| ES2912881T3 (es) * | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| JP2019537601A (ja) * | 2016-11-02 | 2019-12-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 新規投薬レジメン |
| MX2019013758A (es) * | 2017-05-19 | 2020-07-20 | Biogen Ma Inc | Formas cristalinas novedosas. |
| CA3076823A1 (en) | 2017-10-05 | 2019-04-11 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| CA3077088A1 (en) | 2017-10-10 | 2019-04-18 | Biogen Inc. | Process for preparing spiro derivatives |
| KR20210002472A (ko) * | 2018-04-16 | 2021-01-08 | 바이오젠 엠에이 인코포레이티드 | 신경병증성 통증을 치료하는 방법 |
| MX2021012421A (es) * | 2019-04-10 | 2022-02-10 | Biogen Inc | Procesos para preparar derivados de pirrolidina alfa-carboxamida. |
| AU2020271856A1 (en) * | 2019-04-10 | 2021-12-02 | Biogen Ma Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| US12544385B2 (en) | 2020-01-30 | 2026-02-10 | Mohammad JAVED | Combination drug therapies for CNS disorders |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| US6136131A (en) * | 1998-06-02 | 2000-10-24 | Instrument Specialties Company, Inc. | Method of shielding and obtaining access to a component on a printed circuit board |
| CA2368631A1 (en) | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
| MY134480A (en) | 2002-09-20 | 2007-12-31 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| JP2006522130A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール |
| EP1618099A4 (en) | 2003-04-18 | 2008-07-16 | Merck & Co Inc | BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| WO2005100334A1 (en) | 2004-04-14 | 2005-10-27 | Pfizer Products Inc. | Dipeptidyl peptidase-iv inhibitors |
| EP1877381A1 (en) | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| US7858786B2 (en) | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
| WO2006124865A2 (en) | 2005-05-19 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Biaryls derivatives useful as modulators of ion channels |
| EP1928886B1 (en) | 2005-09-09 | 2011-04-13 | GlaxoSmithKline LLC | Pyridine derivatives and their use in the treatment of psychotic disorders |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| ATE472529T1 (de) * | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136986A patent/TW200730494A/zh unknown
- 2006-10-06 EP EP06806110A patent/EP1934177B8/en active Active
- 2006-10-06 NZ NZ567051A patent/NZ567051A/en unknown
- 2006-10-06 WO PCT/EP2006/009731 patent/WO2007042239A1/en not_active Ceased
- 2006-10-06 AT AT06806110T patent/ATE556049T1/de active
- 2006-10-06 AU AU2006301470A patent/AU2006301470B2/en not_active Ceased
- 2006-10-06 PL PL06806110T patent/PL1934177T3/pl unknown
- 2006-10-06 ES ES06806110T patent/ES2387405T3/es active Active
- 2006-10-06 BR BRPI0616944A patent/BRPI0616944B8/pt not_active IP Right Cessation
- 2006-10-06 JP JP2008534910A patent/JP5139305B2/ja not_active Expired - Fee Related
- 2006-10-06 KR KR1020087011271A patent/KR101282464B1/ko not_active Expired - Fee Related
- 2006-10-06 US US11/570,560 patent/US7655693B2/en active Active
- 2006-10-06 PE PE2006001225A patent/PE20070592A1/es not_active Application Discontinuation
- 2006-10-06 CA CA2625642A patent/CA2625642C/en active Active
- 2006-10-06 EA EA200801054A patent/EA015736B1/ru not_active IP Right Cessation
- 2006-10-09 AR ARP060104441A patent/AR056575A1/es not_active Application Discontinuation
-
2008
- 2008-03-31 MA MA30797A patent/MA29817B1/fr unknown
- 2008-04-18 CR CR9898A patent/CR9898A/es not_active Application Discontinuation
- 2008-05-07 NO NO20082145A patent/NO20082145L/no not_active Application Discontinuation
- 2008-07-03 IL IL192627A patent/IL192627A0/en active IP Right Grant
-
2009
- 2009-12-17 US US12/641,111 patent/US8153681B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20080280969A1 (en) | 2008-11-13 |
| NO20082145L (no) | 2008-05-07 |
| BRPI0616944B1 (pt) | 2020-04-14 |
| WO2007042239A1 (en) | 2007-04-19 |
| EP1934177A1 (en) | 2008-06-25 |
| EP1934177B1 (en) | 2012-05-02 |
| PE20070592A1 (es) | 2007-06-23 |
| IL192627A0 (en) | 2011-08-01 |
| NZ567051A (en) | 2011-03-31 |
| ATE556049T1 (de) | 2012-05-15 |
| JP2009511519A (ja) | 2009-03-19 |
| JP5139305B2 (ja) | 2013-02-06 |
| EA015736B1 (ru) | 2011-10-31 |
| CA2625642C (en) | 2013-12-24 |
| PL1934177T3 (pl) | 2013-03-29 |
| EP1934177B8 (en) | 2012-09-05 |
| ES2387405T3 (es) | 2012-09-21 |
| AU2006301470A1 (en) | 2007-04-19 |
| BRPI0616944B8 (pt) | 2021-05-25 |
| US8153681B2 (en) | 2012-04-10 |
| EA200801054A1 (ru) | 2008-08-29 |
| KR101282464B1 (ko) | 2013-07-04 |
| CR9898A (es) | 2008-07-29 |
| AU2006301470B2 (en) | 2012-06-14 |
| CA2625642A1 (en) | 2007-04-19 |
| BRPI0616944A2 (pt) | 2011-07-05 |
| AR056575A1 (es) | 2007-10-10 |
| US20100105754A1 (en) | 2010-04-29 |
| TW200730494A (en) | 2007-08-16 |
| KR20080059296A (ko) | 2008-06-26 |
| US7655693B2 (en) | 2010-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29817B1 (fr) | Derives de prolinamide utilises comme modulateurs du canal sodium | |
| BRPI0410711A (pt) | novos compostos | |
| EA200600203A1 (ru) | Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2 | |
| BRPI0719590A2 (pt) | Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio | |
| EA200501771A1 (ru) | Лиганды каннабиноидных рецепторов и их применения | |
| MX2009002002A (es) | Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio. | |
| PT1206474E (pt) | Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 | |
| MA29870B1 (fr) | Nouveaux dérivés de 1-azabicycloalkyles dans le traitement de troubles psychotiques et neurodégénératifs | |
| DZ3265A1 (fr) | Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2 | |
| MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
| MA31906B1 (fr) | Inhibiteurs de la replication du virus de limmunodeficience humaine | |
| EA200970575A1 (ru) | Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения | |
| EA201290267A1 (ru) | Производные диоксабицикло[3.2.1]октан-2,3,4-триола | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| ES2171723T3 (es) | 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2. | |
| CR8926A (es) | Acidos de tiazolo-naftilo | |
| ATE472529T1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
| NO20063064L (no) | Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte | |
| MA27111A1 (fr) | Derives de benzofurane et de benzothiophene utilises dans le traitement de troubles hyperproliferatifs | |
| BR0105563A (pt) | Derivados e análogos de galantamina | |
| TW200728258A (en) | Novel compounds | |
| ATE372114T1 (de) | Verfahren zur erhöhung des testosteronspiegels | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
| ATE457724T1 (de) | Alpha-aminoamid derivate zur verwendung als anti- inflammatorische wirkstoffe |